A composite decision rule of CD8+ T cell density in tumor biopsies predicts efficacy in early-stage, immunotherapy trials.

David Dejardin Anton Kraxner Annika Blank Natascha Rieder Volker Teichgräber Nicolas Städler Ulrich Beyer Bruno Gomes Jehad Charo

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

We propose that a composite score of CD8+ T cell density in paired biopsies taken before and on-treatment may be a new biomarker to inform on clinical outcomes in early immunotherapy clinical trials.

Keyphrases

early stage
clinical trial
ultrasound guided
randomized controlled trial
sentinel lymph node
radiation therapy
combination therapy
rectal cancer
phase iii